Gilead Launches First Bond Offering in 18 Months

Gilead Sciences announced its first investment‑grade bond issuance in 18 months, offering up to four tranches with 2‑ to 8‑year maturities.
The longest‑tenor tranche is priced at a yield 0.8 percentage points above U.S. Treasuries, with proceeds earmarked for general corporate purposes, including acquisitions.
The company expects $11.5 billion of acquisition‑related charges this year, notably funding the purchase of German biotech Tubulis GmbH via senior unsecured notes.
The bond sale is being managed by Barclays, Bank of America and Citigroup, following Gilead’s previous $3.5 billion high‑grade raise in November 2024.